CONMED Corp. Stock
CONMED Corp. Stock
CONMED Corp. gained 0.670% compared to yesterday.
Our community is currently high on CONMED Corp. with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 53 € shows a very positive potential of 76.67% compared to the current price of 30.0 € for CONMED Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for CONMED Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of CONMED Corp. in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CONMED Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CONMED Corp. | 0.670% | -1.316% | -3.846% | -39.024% | -14.286% | -74.576% | -72.477% |
| Haemonetics Corp. | 2.480% | 5.983% | 30.252% | - | -9.489% | - | - |
| Bio-Rad Labs Inc. A | -2.640% | -6.515% | 16.091% | 31.548% | -0.969% | -26.525% | -46.792% |
| Glaukos Corp | -1.540% | 5.495% | -17.241% | 17.073% | -0.518% | 66.957% | 61.345% |
Comments
CONMED (CNMD) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (CNMD) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (NYSE:CNMD) had its price target lowered by analysts at Piper Sandler from $68.00 to $55.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CNMD provided by MarketBeat